What is Zacks Research's Estimate for GSK FY2025 Earnings?

GSK plc (NYSE:GSK - Free Report) - Zacks Research boosted their FY2025 earnings per share estimates for shares of GSK in a note issued to investors on Wednesday, February 26th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings of $4.14 per share for the year, up from their prior estimate of $4.12. The consensus estimate for GSK's current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK's Q4 2025 earnings at $0.76 EPS.

A number of other brokerages have also recently issued reports on GSK. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and cut their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to MarketBeat.com, GSK presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Stock Performance

Shares of GSK stock traded up $0.38 during trading hours on Monday, reaching $37.97. The company had a trading volume of 3,978,664 shares, compared to its average volume of 4,929,240. The firm has a market cap of $78.70 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. GSK has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The business has a fifty day simple moving average of $34.99 and a 200 day simple moving average of $37.23.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.14%. GSK's payout ratio is presently 98.74%.

Hedge Funds Weigh In On GSK

A number of hedge funds and other institutional investors have recently bought and sold shares of GSK. US Bancorp DE grew its position in GSK by 12.2% in the third quarter. US Bancorp DE now owns 236,770 shares of the pharmaceutical company's stock worth $9,679,000 after acquiring an additional 25,781 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its holdings in shares of GSK by 13.6% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 11,814 shares of the pharmaceutical company's stock worth $483,000 after purchasing an additional 1,410 shares in the last quarter. Van ECK Associates Corp increased its position in shares of GSK by 8.4% during the 3rd quarter. Van ECK Associates Corp now owns 736,510 shares of the pharmaceutical company's stock valued at $27,973,000 after purchasing an additional 56,843 shares during the last quarter. BSW Wealth Partners bought a new position in shares of GSK during the 3rd quarter valued at about $223,000. Finally, Forum Financial Management LP purchased a new position in shares of GSK during the 3rd quarter valued at about $204,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.